Literature DB >> 19283851

Cidofovir induces an increase in levels of low-risk and high-risk HPV E6.

Adam J Donne1, Lynne Hampson, Xiaotong T He, Michael P Rothera, Jarrod J Homer, Ian N Hampson.   

Abstract

BACKGROUND: Cidofovir is a nucleoside analogue that is used off-license to treat recurrent respiratory papillomatosis (RRP) caused by HPV6/11. However, the effect of this drug upon low-risk HPV 6/11 gene expression is unknown.
METHODS: The expression of E6 was evaluated by RT-PCR in HPV-ve C33A cervical carcinoma cells stably transfected with both low- and high-risk HPV E6 cDNA's and in SiHa (HPV16+ve) cervical carcinoma cells after treatment with 2 doses and durations of exposure to cidofovir.
RESULTS: Compared to the vector only transcript, E6 RNA levels showed an 8-fold increase in low-risk and 20-fold increase in high-risk E6-expressing cells. High-risk E6 protein levels were also detected by Western blot in cidofovir-treated C33A Type16 E6-transfected cells.
CONCLUSION: These data may indicate a potential rationale for increased risk of genetic instability and thus transformation due to drug-induced increase in the level of E6.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283851     DOI: 10.1002/hed.21043

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

Review 1.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

2.  Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

Authors:  Elizabeth A Stier; Stephen E Goldstone; Mark H Einstein; Naomi Jay; John M Berry; Timothy Wilkin; Jeannette Y Lee; Teresa M Darragh; Maria Da Costa; Lori Panther; David Aboulafia; Joel M Palefsky
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

3.  Inhibition of antiviral drug cidofovir on proliferation of human papillomavirus-infected cervical cancer cells.

Authors:  Jing Yang; Lv-Xia Dai; Ming Chen; Bei Li; Nana Ding; Gang Li; Yan-Qing Liu; Ming-Yuan Li; Bao-Ning Wang; Xin-Li Shi; Hua-Bing Tan
Journal:  Exp Ther Med       Date:  2016-09-20       Impact factor: 2.447

4.  Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.

Authors:  Tim De Schutter; Graciela Andrei; Dimitri Topalis; Lieve Naesens; Robert Snoeck
Journal:  BMC Med Genomics       Date:  2013-05-23       Impact factor: 3.063

5.  HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis.

Authors:  Paul Stefan Mauz; Fabian Axel Schäfer; Thomas Iftner; Phillipp Gonser
Journal:  BMC Infect Dis       Date:  2018-07-24       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.